Radiosynthesis and evaluation of ytterbium-175 labeled bleomycin as therepeutic agent

Document Type: Original Article

Authors

1 Department of Nuclear Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

2 Nuclear Science Research School, Nuclear Science and Technology Research Institute, Tehran, Iran AND Radiopharmaceutical Research and Development Lab, Nuclear Science and Technology Research Institute, Tehran, Iran

3 Radiopharmaceutical Research and Development Lab, Nuclear Science and Technology Research Institute, Tehran, Iran

4 Nuclear Science Research School, Nuclear Science and Technology Research Institute, Tehran, Iran

Abstract

Introduction: Bleomycins are DNA-binding biomolecules, which can be used as targeted therapy carriers when labeled with particle-emitters such as Yb-175. In this work the development of Yb-175 bleomycin (175Yb-BLM) has been reported.
Methods: Yb-175 chloride was obtained by thermal neutron irradiation (3 × 1013 n.cm-2.s-1) of natural Yb2O3 samples at various neutron fluxes and irradiation times. The radionuclide dissolved in acidic media (120mCi/mg) was used in the bleomycin (5 mg) labeling in buffer solution and warming at 60ºC for 48 h. Radiochemical purity was determined by ITLC as well as specific activity calculation followed by stability studies. Biodistribution studies of free Yb-175 and 175Yb-BLM were performed in wild-type mice up to 8 days.
Results: At optimized conditions radiochemical purity of 97±0.88 % and specific activity of 1360 MBq/mM was obtained. Biodistribution studies of free Yb-175 demonstrated liver and bone uptake while in case of 175Yb-BLM the target tissues were lung, liver and spleen.

Conclusion: 175Yb-BLM complex was prepared at the optimized conditions and suitable characteristics. The accumulation of the radiolabeled compound in lungs, liver and spleen demonstrates a similar pattern to the other radiolabeled bleomycins. Further studies are to be performed for application of this labeled compound in tumor-bearing models.

Keywords

Main Subjects


Korppi-Tommola T, Huhmar H, Aronen HJ, Penttilä P, Hiltunen J, Savolainen S, Kallio ME, Liewendahl K. 111In-labelled bleomycin complex for the differentiation of high- and low-grade gliomas. Nucl Med Commun. 1999 Feb;20(2):145-52.

Zolghadri S, Jalilian AR, Yousefnia H, Bahrami-Samani A, Shirvani-Arani S, Ghannadi-Maragheh M. Development of 166Ho bleomycin as a possible therapeutic complex. J Radioanal Nucl Chem. 2010;285:461–467.

Stern PH, Helpern SE, Hagan PL, Howell SB, Dabbs JE, Gordon RM. Cytotoxic activity, tumor accumulation, and tissue distribution of ruthenium-103-labeled bleomycin. J Natl Cancer Inst. 1981 May;66(5):807-11.

Yousefnia H, Jalilian AR, Zolghadri S, Bahrami-Samani A, Shirvani-Arani S, Ghannadi-Maragheh M. Preparation and quality control of lutetium-177 bleomycin as a possible therapeutic agent. Nukleonika 2010; 55(3):285−291.

Brooks RC, Carnochan P, Vollano JF, Powell NA, Zweit J, Sosabowski JK, Martellucci S, Darkes MC, Fricker SP, Murrer BA. Metal complexes of bleomycin: evaluation of [Rh-105]-bleomycin for use in targeted radiotherapy. Nucl Med Biol. 1999 May;26(4):421-30.

Mathew B, Chakraborty S, Das T, Sarma HD, Banerjee S, Samuel G, Venkatesh M, Pillai MR. 175Yb labeled polyaminophosphonates as potential agents for bone pain palliation. Appl Radiat Isot. 2004 May;60(5):635-42.

Chakraborty S, Das T, Banerjee S, Subramanian S, Sarma HD, Venkatesh M. 175Yb-labeled hydroxyapatite: a potential agent for use in radiation synovectomy of small joints. Nucl Med Biol. 2006 May;33(4):585-91.

Firestone RB, Chu SYF, Baglin CM. Table of isotopes.  8th Ed. New York: John Wiley and Sons Inc.; 1998.

Chakraborty S, Unni PR, Venkatesh M, Pillai MR. Feasibility study for production of 175Yb: a promising therapeutic radionuclide. Appl Radiat Isot. 2002 Sep;57(3):295-301.

Bahrami-Samani A, Anvari A, Jalilian AR, Shirvani-Arani S, Yousefnia H, Aghamiri MR, Ghannadi-Maragheh M, Production, quality control and pharmacokinetic studies of 177Lu-EDTMP for human bone pain palliation therapy trials. Iran J Pharm Res. 2012;11(1):137-144.

Takita T, Metal complex of bleomycin and its implication for the mechanism of bleomycin action.  In: Hect SM. Bleomycin: chemical, biochemical, and biological aspects. New York: Springer; 1979. P. 156-64.

Moghaddam-Banaem L, Jalilian AR, Pourjavid M, Bahrami-Samani A, Mazidi M, Ghannadi-Maragheh M. Preparation and quality control of scandium-46 bleomycin as a possible therapeutic agent. Iran J Nucl  Med. 2012;20(1):19-24.

Jalilian AR, Rowshanfarzad P, Sabet M, Novinrooz A, Raisali G. Preparation of [66Ga]bleomycin complex as a possible PET radiopharmaceutical. J Radioanal Nucl Chem 2005;264(3):617-621.

Melnyk DL, Horwitz SB, Peisach T. The oxidation-reduction potential of copper-bleomycin. Inorgan Chim Acta. 1987;138:75-78.

Antholine WE, Solaiman D, Saryan LA, Petering DH. Studies on the chemical reactivity of copper bleomycin. J Inorg Biochem. 1982 Oct;17(2):75-94.

Eckelman WC, Rzeszotarski WJ, Siegel BA, Kubota H, Chelliah M. The chemical and biological properties of isolated radiolabeled bleomycin components, Armed Forces Radiobiology Research Inst Bethesda MD, Report date: DEC 1975 Accession number: ADA021834.